Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global N Sulphoglucosamine Sulphohydrolase Pipeline Review 2016 - Research and Markets

Research and Markets
Posted on: 03 Oct 16

Research and Markets has announced the addition of the "N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016" report to their offering.

N Sulphoglucosamine Sulphohydrolase pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.

N Sulphoglucosamine Sulphohydrolase N-sulphoglucosamine sulphohydrolase is an enzyme encoded by the SGSH gene. This enzyme is involved in the lysosomal degradation of heparan sulfate. Mutations in this gene are associated with Sanfilippo syndrome A, one type of the lysosomal storage disease mucopolysaccaridosis III.

The report 'N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H2 2016' outlays comprehensive information on the targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies

Universities.

It also reviews key players involved in N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II and Preclinical stages are 5 and 1 respectively.

Key Topics Covered:

  1. Introduction
  2. N Sulphoglucosamine Sulphohydrolase Overview
  3. Therapeutics Development
  4. Pipeline Products for N Sulphoglucosamine Sulphohydrolase - Overview
  5. Pipeline Products for N Sulphoglucosamine Sulphohydrolase - Comparative Analysis
  6. N Sulphoglucosamine Sulphohydrolase - Therapeutics under Development by Companies
  7. N Sulphoglucosamine Sulphohydrolase - Therapeutics under Investigation by Universities/Institutes
  8. N Sulphoglucosamine Sulphohydrolase Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. N Sulphoglucosamine Sulphohydrolase - Products under Development by Companies
  13. N Sulphoglucosamine Sulphohydrolase - Products under Investigation by Universities/Institutes
  14. N Sulphoglucosamine Sulphohydrolase - Companies Involved in Therapeutics Development
  • Abeona Therapeutics, Inc.
  • ArmaGen Inc.
  • Laboratorios Del Dr. Esteve S.A.
  • Lysogene
  • Shire Plc

For more information about this report visit http://www.researchandmarkets.com/research/284zz8/n

View source version on businesswire.com: http://www.businesswire.com/news/home/20161003006253/en/

Business Wire
www.businesswire.com

Last updated on: 03/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.